{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:33:02Z","timestamp":1772155982672,"version":"3.50.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shenyang Major Science and Technology Innovation R&amp;D Program","award":["JY2020-9-018 to Y.Chen"],"award-info":[{"award-number":["JY2020-9-018 to Y.Chen"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Coronavirus disease 2019 (COVID-19) is an emerging disease caused by severe acute respiratory syndrome coronavirus 2; no specific effective medication to treat the disease has been identified to date. We aimed to investigate the administered medications and intervention times for patients who completely recovered from COVID-19.<\/jats:p>\n                    <jats:p>This single-center, retrospective, observational study included 55 patients with COVID-19 who were transferred to Shenyang Sixth People's Hospital between January 20 and March 15, 2020. Data on demographics, symptoms, laboratory indicators, treatment processes, and clinical outcomes were collected. Administered drugs and intervention times were compared in 47 and 8 patients with mild and severe symptoms, respectively.<\/jats:p>\n                    <jats:p>All 55 patients recovered. Fifty-three patients (96.36%) received antiviral therapy, including 45 in the mild group (median treatment: 14 days; 17 received umifenovir) and all 8 severe-group patients (median treatment: 17.5 days; 4 received lopinavir\/ritonavir). Twenty-nine patients (52.72%) were administered antibiotics, including 21 in the mild group (median treatment: 13.5 days; 15 received moxifloxacin) and all 8 in the severe group (median treatment: 9 days; 2 received linezolid). Moreover, 7 patients (12.72%) were treated with glucocorticoids and 9 (16.36%) with immunomodulators.<\/jats:p>\n                    <jats:p>Given the 100% recovery rate, early administration of antiviral drugs can be considered. Umifenovir may benefit patients with mild symptoms, while lopinavir\/ritonavir may benefit those with severe symptoms. Prophylactic administration of common antibiotics may reduce the risk of co-infection. The use of glucocorticoids is usually not necessary. Randomized, double-blind, and controlled trials remain necessary for more accurate conclusions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000023923","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:04:12Z","timestamp":1610622252000},"page":"e23923","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered"],"prefix":"10.1097","volume":"100","author":[{"given":"Lichao","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Tuberculosis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Central Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shenyang Tenth People's Hospital, Shenyang Chest Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Respiratory, Shenyang Sixth People's Hospital, Shenyang 110044, Liaoning, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shenyang Tenth People's Hospital, Shenyang Chest Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3948-7875","authenticated-orcid":false,"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMc2001621","article-title":"Journey of a Thai taxi driver and novel coronavirus","volume":"382","author":"Pongpirul","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent Sci"},{"key":"R3-20250504","article-title":"COVID-19 diagnosis and treatment plan (trial version 5)","year":"2020","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/aps.2013.54","article-title":"Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection","volume":"34","author":"Liu","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"R6-20250504","first-page":"274","article-title":"In vitro experimental study on the effect of Arbidol against SARS virus","volume":"20","author":"Ji","year":"2004","journal-title":"Pharm J Chin PLA"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14787210.5.1.13","article-title":"Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections","volume":"5","author":"Tan","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jtbi.2008.07.030","article-title":"Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CLpro inhibitors","volume":"254","author":"Nukoolkarn","year":"2008","journal-title":"J Theor Biol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J Infect Dis"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1073\/pnas.0508200103","article-title":"Discovery of an RNA virus 3\u2032\u200a\u2192\u200a5\u2032 exoribonuclease that is critically involved in coronavirus RNA synthesis","volume":"103","author":"Minskaia","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e1003565","DOI":"10.1371\/journal.ppat.1003565","article-title":"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics","volume":"9","author":"Smith","year":"2013","journal-title":"PLoS Pathog"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/cid\/ciz544","article-title":"Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study","volume":"70","author":"Arabi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1164\/rccm.201101-0110OC","article-title":"Corticosteroid treatment in critically ill patients with pandemic influenza A\/H1N1 2009 infection: analytic strategy using propensity scores","volume":"183","author":"Kim","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1164\/rccm.200305-707OE","article-title":"Our strategies for fighting severe acute respiratory syndrome (SARS)","volume":"168","author":"Zhong","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R17-20250504","first-page":"352","article-title":"MERS Diagnosis and Treatment Plan (2015)","volume":"5","year":"2015","journal-title":"Zhongguo Bing Du Bing Za Zhi"},{"key":"R18-20250504","first-page":"253","article-title":"Guidelines for the diagnosis and treatment of community-acquired pneumonia in Chinese adults (2016 edition)","volume":"39","year":"2016","journal-title":"Chin J Tuberc Respir Med [Zhonghua Jie He He Hu Xi Za Zhi]"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1086\/591708","article-title":"Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness","volume":"198","author":"Morens","year":"2008","journal-title":"J Infect Dis"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/CCM.0b013e3182416f23","article-title":"Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States","volume":"40","author":"Rice","year":"2012","journal-title":"Crit Care Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/JCMA.0000000000000375","article-title":"Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019","volume":"83","author":"Kuan-Hsuana","year":"2020","journal-title":"J Chin Med Assoc"},{"key":"R22-20250504","first-page":"2150","article-title":"Thymosin alpha 1 (T\u03b11) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells","volume":"71","author":"Yueping","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:23:31Z","timestamp":1746325411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023923"}},"subtitle":["A single-center, retrospective, observational study"],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023923","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.28.20045955","asserted-by":"object"}]},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"2020-06-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}